Around 66 million registered residents under near-universal health coverage, ICH-aligned regulatory standards, world-leading tropical medicine research through Mahidol University and MORU, unique niches in cholangiocarcinoma and thalassemia, and per-patient costs far below Western equivalents.
Thailand is a constitutional monarchy of around 66 million registered residents at the geographic centre of mainland Southeast Asia, sharing borders with Myanmar, Laos, Cambodia, and Malaysia, with dual coastlines on the Gulf of Thailand and the Andaman Sea. The country's clinical research geography divides along four major corridors. Bangkok, the capital, is the dominant hub; home to Siriraj Hospital, Ramathibodi Hospital, King Chulalongkorn Memorial Hospital, the National Cancer Institute, and the world-class private hospitals of Bumrungrad International and the Bangkok Hospital network. Khon Kaen in the northeast is the world reference centre for cholangiocarcinoma research through Khon Kaen University's Faculty of Medicine and CASCAP programme. Chiang Mai in the north anchors Thailand's HIV, tropical disease, and hill-tribe population research through Chiang Mai University and the Research Institute for Health Sciences (RIHES). Hat Yai (Songkhla province) in the south provides ASEAN cross-border patient access through Prince of Songkla University's Songklanagarind Hospital.
Clinical trials are regulated by the Food and Drug Administration of Thailand (Thai FDA), operating under the Ministry of Public Health; an experienced regulator whose standards are formally aligned with ICH E6(R2) GCP and ICH E8, E9, and other technical guidelines. Ethics review is provided through institutional ethics committees (IECs) at each hospital, with the Thai Clinical Trials Registry (TCTR); a WHO primary registry; providing the national trial registration framework. Thailand's most structurally distinctive feature for clinical research is its near-universal health coverage: the Universal Coverage Scheme (UCS) extends subsidised healthcare to approximately 48 million Thais; combined with the Civil Servant Medical Benefit Scheme (~5 million) and Social Security Scheme (~14 million), Thailand achieves approximately 99% population health coverage.
Thailand's population is approximately 94% ethnic Thai, with a significant Sino-Thai community (~14% with Chinese ancestry, fully integrated into Thai identity), Malay Muslim communities in the southern border provinces (~5%), and smaller hill-tribe communities in the northern highlands (Karen, Hmong, Akha, and others) whose genetic isolation and distinct disease exposures create unique research sub-populations. The median age is approximately 40 years; relatively young for the level of economic development. Investigator English proficiency at academic research centres is good to strong; Thai medical researchers train internationally, publish in English, and communicate with sponsors in English as a professional standard; patient-facing materials require Thai-language adaptation.
Thailand's disease burden creates some of the most clinically distinctive research opportunities in Asia. Infectious and tropical diseases; dengue fever, malaria, tuberculosis, and HIV; have shaped Thai research institutions into world-class infectious disease investigation centres. Non-communicable disease is a rapidly growing second axis: cardiovascular disease is now the leading cause of death (~30% of mortality), Type 2 diabetes prevalence has reached approximately 9% of adults, and cancer; particularly hepatocellular carcinoma and cholangiocarcinoma in the northeast; represents a uniquely Thai oncological landscape. Thalassaemia is one of the world's most severe public health challenges in Thailand: an estimated 30 to 40% of the Thai population carry at least one thalassaemia gene, with hundreds of thousands living with clinically significant disease.
Two conditions the world cannot study at depth anywhere but Thailand: With approximately 30 to 40% of Thais carrying at least one thalassaemia gene mutation and an estimated 100,000+ living with clinically significant beta-thalassaemia/haemoglobin E or severe alpha-thalassaemia, Thailand offers patient volumes for haemoglobinopathy clinical trials that no European country approaches. And the Isan (northeastern) region records the world's highest incidence of cholangiocarcinoma (bile duct cancer); driven by Opisthorchis viverrini liver fluke infection; at rates 5 to 10 times higher than any other country on Earth. Khon Kaen University's CASCAP has built the world's only large-scale CCA patient registry, making Thailand's northeast the sole viable platform globally for pivotal Phase II to III trials in opisthorchiasis-associated cholangiocarcinoma.
Thailand occupies a singular position in Asian clinical research: a country that combines the patient scale of a 66-million-plus universal-coverage health system, the regulatory credibility of ICH-aligned standards, world-class academic tropical medicine infrastructure, two globally unique disease research niches, a world-famous private hospital sector with international GCP familiarity, and per-patient costs a fraction of European or US equivalents.
Thai FDA is a full ICH Regulatory Member since 2016, with regulatory standards aligned with ICH E6(R2) GCP, E8, E9, and other technical guidelines; Thai Clinical Trials Registry (TCTR) is a WHO primary registry; institutional ethics committees (IECs) at all major research hospitals operate under ICH-GCP framework; Thai FDA's approval process has been modernising continuously since ICH membership, with timelines competitive within Southeast Asia; regulatory data generated in Thailand is accepted in ICH-member jurisdiction submissions.
Per-patient and operational costs typically 60 to 80% below Western European and US equivalents; investigator fees, hospital overhead, and clinical staff costs substantially lower while maintaining ICH-GCP quality standards; growing CRO infrastructure in Bangkok with competitive local and regional management fees; Thai Baht relative stability reducing currency risk for USD- and EUR-denominated trial budgets; ASEAN market positioning enabling efficient regional trial network design spanning Thailand, Malaysia, and Vietnam within a single budget framework.
Around 66 million registered residents under ~99% health coverage creating a nationally structured patient access system; large treatment-naive pools across cardiovascular, metabolic, oncological, and infectious disease; with hepatocellular carcinoma and cholangiocarcinoma patients substantially less pre-treated than equivalent Western populations; world's largest thalassaemia patient population for haemoglobinopathy trials; globally unique cholangiocarcinoma population in Isan; Asian pharmacogenomic profile relevant for ethnically diverse global trial designs; HIV landmark research tradition creating exceptionally experienced infectious disease investigators.
Siriraj Hospital (Thailand's largest, one of Asia's oldest academic hospitals) as the national research anchor; Mahidol University Faculty of Tropical Medicine and MORU (Mahidol-Oxford Research Unit) as world-class tropical infectious disease infrastructure; Khon Kaen University CASCAP as the world reference for cholangiocarcinoma research and thalassaemia registry; Bumrungrad International and Bangkok Hospital networks providing JCI-accredited private hospital research capacity with extensive international sponsor experience; four geographically distributed university hospital research corridors covering the full Thai patient catchment.
Infectious and tropical disease is Thailand's most globally distinctive research domain; a research identity built over five decades through the Mahidol University Faculty of Tropical Medicine, MORU, and landmark contributions to malaria (artemisinin combination therapy), dengue, and HIV (Thailand was the site of the RV144 HIV vaccine trial, still the only trial to demonstrate any vaccine efficacy against HIV). Oncology is the second major pillar, driven by hepatocellular carcinoma and the world-reference cholangiocarcinoma programme at Khon Kaen. Haematology, anchored by thalassaemia research at Khon Kaen's National Centre for Blood Diseases, and the rapidly growing metabolic disease burden each represent research areas with large, engaged, largely treatment-naive patient pools.
Bangkok dominates Thai clinical research through an unusually diverse mix of public university hospitals; Siriraj (Mahidol) and King Chulalongkorn Memorial (Chulalongkorn) as the two primary academic anchors; and a private hospital sector of international calibre with Bumrungrad International and the Bangkok Hospital network operating at JCI-accredited quality standards. Khon Kaen, Chiang Mai, and Hat Yai provide geographically distributed and therapeutically distinctive nodes.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Siriraj Hospital; Faculty of Medicine Siriraj, Mahidol University | Bangkok | Thailand's largest hospital and one of Asia's oldest academic medical institutions, founded in 1888; Mahidol University Faculty of Medicine Siriraj affiliate; Phase I to IV across oncology, haematology, infectious disease, cardiovascular, nephrology, neurology, and rare diseases; home to over 40 research centres and units including a dedicated clinical trial infrastructure; the most internationally connected major trial site in Thailand and the primary national research anchor for commercial Phase I to III programs across all therapeutic areas; consistently among the highest-enrolling sites in any Thailand-inclusive multinational clinical trial. |
| 02 | Ramathibodi Hospital; Faculty of Medicine Ramathibodi, Mahidol University | Bangkok | Mahidol University's second major academic hospital, with one of Thailand's most comprehensive clinical trial portfolios; Phase I to IV across oncology, haematology, cardiovascular, internal medicine, gastroenterology, and neurology; home of the Ramathibodi Comprehensive Cancer Centre; a major Phase I to III oncology research hub whose hepatocellular carcinoma and lung cancer programs are among the most active in Southeast Asia; strong investigator-initiated research tradition in haematological malignancies and solid tumours, with established partnerships with major global oncology pharmaceutical companies. |
| 03 | King Chulalongkorn Memorial Hospital (KCMH) | Bangkok | Thailand's second major academic hospital system and the primary clinical institution of Chulalongkorn University Faculty of Medicine; Phase I to IV across oncology, cardiovascular, endocrinology, rheumatology, and haematology; affiliated with the Thai Red Cross Society and home to the Thai Red Cross AIDS Research Centre; one of Southeast Asia's most experienced HIV clinical research institutions; the KCMH oncology programme has been central to Thailand's participation in international Phase III oncology trials across breast, gastrointestinal, and lung cancer indications. |
| 04 | Phramongkutklao Hospital | Bangkok | Thailand's primary military teaching hospital and one of the country's most internationally connected infectious disease and tropical medicine research sites; Phase II to IV across infectious disease, HIV, malaria, and internal medicine; has maintained long-standing research collaborations with the Walter Reed Army Research Institute (WRAIR) and the US Army Medical Component in Thailand; partnerships that produced landmark HIV prevention and tropical medicine trials over four decades; the Phramongkutklao site played an institutional role in the RV144 HIV vaccine trial, the first to demonstrate any efficacy against HIV infection. |
| 05 | National Cancer Institute Thailand (NCI) | Bangkok | Thailand's dedicated national cancer hospital under the Department of Medical Services, Ministry of Public Health; Phase I to IV across solid tumours (hepatocellular carcinoma, cervical, colorectal, lung, and breast cancer), haematological malignancies, and radiotherapy-combined programs; the NCI functions as the national oncology policy and clinical reference institution and provides sponsors with access to Thailand's national cancer patient referral network; active in ASEAN oncology cooperative research networks and in bilateral clinical trial partnerships with Japanese, Korean, and European cancer research consortia. |
| 06 | Bumrungrad International Hospital | Bangkok | Thailand's premier private international hospital; receiving over one million patients annually including approximately 600,000 international patients from over 190 countries; and one of Southeast Asia's most internationally experienced clinical trial sites; fully JCI-accredited; Phase II to IV across oncology, cardiovascular, metabolic disease, and infectious disease; established relationships with international pharmaceutical company sponsors and experience conducting trials to the highest ICH-GCP standards; Bumrungrad's multilingual clinical trial team, international patient database, and direct access to foreign nationals residing or seeking treatment in Thailand make it uniquely positioned for trials requiring internationally diverse enrollment within a single Asian site. |
| 07 | Srinagarind Hospital; Khon Kaen University | Khon Kaen | Northeast Thailand's major university hospital and the world's institutional reference centre for cholangiocarcinoma (bile duct cancer) research; Khon Kaen University Faculty of Medicine affiliate; Phase I to IV across oncology (particularly biliary and gastrointestinal tumours), haematology (thalassaemia), and infectious disease; home of the CASCAP programme (Cholangiocarcinoma Screening and Care Program); the world's largest CCA patient screening and registry infrastructure; and the National Centre for Blood Diseases, operating Thailand's most comprehensive thalassaemia patient registry; for any sponsor developing therapies in cholangiocarcinoma, haemoglobinopathy, or opisthorchiasis, Srinagarind Hospital is uniquely and irreplaceably the world reference site. |
| 08 | Maharaj Nakhon Chiang Mai Hospital (Suan Dok) | Chiang Mai | Northern Thailand's major university hospital and the primary clinical base of Chiang Mai University Faculty of Medicine; Phase II to IV across HIV, infectious disease, oncology, and internal medicine; works in direct partnership with the Research Institute for Health Sciences (RIHES); one of Asia's most experienced HIV and tropical disease research institutes; whose clinical trial capability in HIV prevention, antiretroviral pharmacology, and emerging pathogen research is internationally recognised; serves diverse northern Thai and hill-tribe populations with genetic and epidemiological characteristics relevant for both infectious disease and pharmacogenomics research. |
| 09 | Songklanagarind Hospital; Prince of Songkla University | Hat Yai | Southern Thailand's university hospital and the clinical base of Prince of Songkla University Faculty of Medicine; Phase II to IV across infectious disease, oncology, cardiovascular, and internal medicine; strategically positioned at Thailand's southern border; proximity to Malaysia creates access to Malay Muslim patient populations with genetic, dietary, and lifestyle characteristics distinct from central Thai populations, providing ethnic diversity of research value for sponsors addressing Asian or pan-ASEAN population diversity in trial design; active in tropical medicine research across the Thai-Malaysian epidemiological corridor. |
| 10 | Chulabhorn Hospital and Research Institute | Bangkok | A royal-foundation research hospital and institute operating under Chulabhorn Royal Academy; Phase II to IV with a focused cancer research mission; the Chulabhorn Research Institute is internationally recognised for environmental carcinogenesis, chemical carcinogen biology, and translational oncology research; areas of particular relevance for hepatocellular carcinoma (aflatoxin and HBV interactions) and cholangiocarcinoma (opisthorchiasis-associated carcinogenesis) mechanisms; the royal-foundation status creates a distinctive research culture and international partnership framework that attracts sponsors seeking academically rigorous mechanistic oncology research alongside commercial trial programs. |
| 11 | Queen Sirikit National Institute of Child Health | Bangkok | Thailand's national paediatric hospital and the primary site for paediatric clinical research; Mahidol University affiliate; Phase II to IV across paediatric HIV (a historically active programme reflecting Thailand's early leadership in paediatric antiretroviral therapy), paediatric dengue and infectious disease, paediatric thalassaemia, and oncology; home of one of Asia's most experienced paediatric HIV research teams, whose longitudinal data on perinatally HIV-infected Thai children has informed global paediatric antiretroviral treatment guidelines; an essential site for sponsors requiring paediatric patient access in Thailand across infectious disease or haematology indications. |
| 12 | Bangkok Hospital Medical Center | Bangkok | The flagship hospital of Bangkok Dusit Medical Services; Thailand's largest private hospital group; and a Phase II to IV clinical research site operating at JCI-accredited international quality standards; oncology, cardiovascular, metabolic disease, and endocrinology trial activity; well-established international sponsor relationships through the Bangkok Hospital network's extensive experience with medical tourism patients from across Asia, the Middle East, and Europe; complements the public university hospital network by offering private-sector research infrastructure with high patient throughput, shorter appointment lead times, and a diverse international patient population for sponsors seeking ethnic enrollment breadth within a single Bangkok site. |
Thailand's largest hospital and one of Asia's oldest academic medical institutions, founded in 1888; Mahidol University Faculty of Medicine Siriraj affiliate; Phase I to IV across oncology, haematology, infectious disease, cardiovascular, nephrology, neurology, and rare diseases; home to over 40 research centres and units including a dedicated clinical trial infrastructure; the most internationally connected major trial site in Thailand and the primary national research anchor for commercial Phase I to III programs across all therapeutic areas; consistently among the highest-enrolling sites in any Thailand-inclusive multinational clinical trial.
Mahidol University's second major academic hospital, with one of Thailand's most comprehensive clinical trial portfolios; Phase I to IV across oncology, haematology, cardiovascular, internal medicine, gastroenterology, and neurology; home of the Ramathibodi Comprehensive Cancer Centre; a major Phase I to III oncology research hub whose hepatocellular carcinoma and lung cancer programs are among the most active in Southeast Asia; strong investigator-initiated research tradition in haematological malignancies and solid tumours, with established partnerships with major global oncology pharmaceutical companies.
Thailand's second major academic hospital system and the primary clinical institution of Chulalongkorn University Faculty of Medicine; Phase I to IV across oncology, cardiovascular, endocrinology, rheumatology, and haematology; affiliated with the Thai Red Cross Society and home to the Thai Red Cross AIDS Research Centre; one of Southeast Asia's most experienced HIV clinical research institutions; the KCMH oncology programme has been central to Thailand's participation in international Phase III oncology trials across breast, gastrointestinal, and lung cancer indications.
Thailand's primary military teaching hospital and one of the country's most internationally connected infectious disease and tropical medicine research sites; Phase II to IV across infectious disease, HIV, malaria, and internal medicine; has maintained long-standing research collaborations with the Walter Reed Army Research Institute (WRAIR) and the US Army Medical Component in Thailand; partnerships that produced landmark HIV prevention and tropical medicine trials over four decades; the Phramongkutklao site played an institutional role in the RV144 HIV vaccine trial, the first to demonstrate any efficacy against HIV infection.
Thailand's dedicated national cancer hospital under the Department of Medical Services, Ministry of Public Health; Phase I to IV across solid tumours (hepatocellular carcinoma, cervical, colorectal, lung, and breast cancer), haematological malignancies, and radiotherapy-combined programs; the NCI functions as the national oncology policy and clinical reference institution and provides sponsors with access to Thailand's national cancer patient referral network; active in ASEAN oncology cooperative research networks and in bilateral clinical trial partnerships with Japanese, Korean, and European cancer research consortia.
Thailand's premier private international hospital; receiving over one million patients annually including approximately 600,000 international patients from over 190 countries; and one of Southeast Asia's most internationally experienced clinical trial sites; fully JCI-accredited; Phase II to IV across oncology, cardiovascular, metabolic disease, and infectious disease; established relationships with international pharmaceutical company sponsors and experience conducting trials to the highest ICH-GCP standards; Bumrungrad's multilingual clinical trial team, international patient database, and direct access to foreign nationals residing or seeking treatment in Thailand make it uniquely positioned for trials requiring internationally diverse enrollment within a single Asian site.
Northeast Thailand's major university hospital and the world's institutional reference centre for cholangiocarcinoma (bile duct cancer) research; Khon Kaen University Faculty of Medicine affiliate; Phase I to IV across oncology (particularly biliary and gastrointestinal tumours), haematology (thalassaemia), and infectious disease; home of the CASCAP programme (Cholangiocarcinoma Screening and Care Program); the world's largest CCA patient screening and registry infrastructure; and the National Centre for Blood Diseases, operating Thailand's most comprehensive thalassaemia patient registry; for any sponsor developing therapies in cholangiocarcinoma, haemoglobinopathy, or opisthorchiasis, Srinagarind Hospital is uniquely and irreplaceably the world reference site.
Northern Thailand's major university hospital and the primary clinical base of Chiang Mai University Faculty of Medicine; Phase II to IV across HIV, infectious disease, oncology, and internal medicine; works in direct partnership with the Research Institute for Health Sciences (RIHES); one of Asia's most experienced HIV and tropical disease research institutes; whose clinical trial capability in HIV prevention, antiretroviral pharmacology, and emerging pathogen research is internationally recognised; serves diverse northern Thai and hill-tribe populations with genetic and epidemiological characteristics relevant for both infectious disease and pharmacogenomics research.
Southern Thailand's university hospital and the clinical base of Prince of Songkla University Faculty of Medicine; Phase II to IV across infectious disease, oncology, cardiovascular, and internal medicine; strategically positioned at Thailand's southern border; proximity to Malaysia creates access to Malay Muslim patient populations with genetic, dietary, and lifestyle characteristics distinct from central Thai populations, providing ethnic diversity of research value for sponsors addressing Asian or pan-ASEAN population diversity in trial design; active in tropical medicine research across the Thai-Malaysian epidemiological corridor.
A royal-foundation research hospital and institute operating under Chulabhorn Royal Academy; Phase II to IV with a focused cancer research mission; the Chulabhorn Research Institute is internationally recognised for environmental carcinogenesis, chemical carcinogen biology, and translational oncology research; areas of particular relevance for hepatocellular carcinoma (aflatoxin and HBV interactions) and cholangiocarcinoma (opisthorchiasis-associated carcinogenesis) mechanisms; the royal-foundation status creates a distinctive research culture and international partnership framework that attracts sponsors seeking academically rigorous mechanistic oncology research alongside commercial trial programs.
Thailand's national paediatric hospital and the primary site for paediatric clinical research; Mahidol University affiliate; Phase II to IV across paediatric HIV (a historically active programme reflecting Thailand's early leadership in paediatric antiretroviral therapy), paediatric dengue and infectious disease, paediatric thalassaemia, and oncology; home of one of Asia's most experienced paediatric HIV research teams, whose longitudinal data on perinatally HIV-infected Thai children has informed global paediatric antiretroviral treatment guidelines; an essential site for sponsors requiring paediatric patient access in Thailand across infectious disease or haematology indications.
The flagship hospital of Bangkok Dusit Medical Services; Thailand's largest private hospital group; and a Phase II to IV clinical research site operating at JCI-accredited international quality standards; oncology, cardiovascular, metabolic disease, and endocrinology trial activity; well-established international sponsor relationships through the Bangkok Hospital network's extensive experience with medical tourism patients from across Asia, the Middle East, and Europe; complements the public university hospital network by offering private-sector research infrastructure with high patient throughput, shorter appointment lead times, and a diverse international patient population for sponsors seeking ethnic enrollment breadth within a single Bangkok site.
These are the primary regulatory, academic, and industry bodies shaping Thailand's clinical research ecosystem.
Thailand's national regulatory authority for clinical trials and pharmaceutical products, operating under the Ministry of Public Health; a full ICH Regulatory Member since 2016, with regulatory guidelines formally aligned with ICH E6(R2) GCP, E8 general considerations, and other technical guidelines; responsible for clinical trial authorisation, GCP inspection, and pharmacovigilance; Thai clinical trial data is generated under internationally recognised regulatory standards accepted across ICH-member jurisdictions including the US FDA, EMA, PMDA, and Health Canada.
Thailand's national clinical trials registry and a WHO primary registry; providing public disclosure of all Thai clinical trials in conformity with WHO International Clinical Trials Registry Platform (ICTRP) standards; mandatory registration under Thai regulatory requirements; TCTR registration is accepted as equivalent to international registry registration for Thai clinical trial reporting in international journals adopting ICMJE policies, ensuring publication accessibility for Thai trial data.
Thailand's governmental body managing the Universal Coverage Scheme (UCS); the 30 Baht Healthcare Scheme that provides near-universal health coverage to approximately 48 million Thais; maintains health utilisation data across the UCS-enrolled population that represents an important secondary data resource for trial feasibility assessment; the NHSO's universal coverage infrastructure creates the patient care pathway continuity that makes large-scale patient identification and follow-up for commercial trials operationally feasible at Thai public hospital sites.
One of the world's foremost tropical medicine research institutions and Thailand's defining research asset in infectious disease; conducts malaria, dengue, melioidosis, leptospirosis, helminthic disease, and emerging pathogen research of global impact; home of the Mahidol-Oxford Tropical Medicine Research Unit (MORU); the Faculty's investigator community represents the most internationally experienced tropical medicine clinical trial team in Southeast Asia.
The Bangkok-based collaborative research unit of Mahidol University and the University of Oxford, operating field stations across Thailand, Myanmar, Laos, Vietnam, Cambodia, and Bangladesh; has generated foundational evidence for artemisinin combination therapy in malaria, optimal drug dosing in tropical infectious diseases, and critical care management in resource-limited settings; an internationally recognised Phase II to III trial platform for sponsors developing antimalarials, antimicrobials, antiparasitics, and critical care therapies.
The world's leading academic institution for cholangiocarcinoma research and thalassaemia clinical investigation; operates CASCAP (Cholangiocarcinoma Screening and Care Program); the world's only large-scale population-based CCA screening and patient registry programme, covering hundreds of thousands of individuals in Opisthorchis viverrini-endemic northeastern Thailand; simultaneously hosts the National Centre for Blood Diseases providing the world's most comprehensive thalassaemia patient registry.
Chiang Mai University's major health research institute, internationally recognised for HIV prevention research, antiretroviral pharmacology, and tropical disease investigation in northern Thai and hill-tribe populations; has conducted landmark HIV prevention trials including pivotal PrEP studies and HIV vaccine Phase I to II investigations; RIHES's long-standing US NIH and international research partnerships have made Chiang Mai a globally connected HIV research hub.
Global CRO with significant Thai operations managing Phase I to IV programs across oncology, infectious disease, metabolic disease, and cardiovascular indications; Thai FDA regulatory submission expertise and institutional ethics committee application support; established site monitoring presence at Siriraj, Ramathibodi, KCMH, and major private hospital networks; regulatory strategy for ICH-member submission design incorporating Thai sites into global development programmes.
International CRO with Thai operations managing Phase II to IV oncology, infectious disease, and metabolic disease programs; established investigator relationships at Siriraj Hospital, Ramathibodi Hospital, the National Cancer Institute, and Bumrungrad International; specialist hepatocellular carcinoma and infectious disease trial experience reflecting Thai sites' core indications; Thai FDA regulatory and IEC ethics application expertise for sponsors activating Thai sites within global or pan-Asian multinational trial designs.
Global CRO with Thai operations providing Phase II to III trial management and regulatory strategy; established site networks across Bangkok university hospitals and private hospital sector; Thai FDA submission expertise for oncology, metabolic disease, and cardiovascular programs; supports sponsors designing ASEAN regional trial networks that include Thailand as the primary enrolling site within a broader Southeast Asian multinational design.
Thailand's dedicated HIV research and innovation institute; a successor organisation to the long-running HIVNAT (HIV Netherlands Australia Thailand) collaboration; providing Phase II to IV HIV prevention, treatment, and cure research capability embedded within Thai clinical research infrastructure; maintains an extensive HIV-positive and HIV-exposed research cohort in Bangkok; for sponsors developing HIV prevention or treatment programs requiring Asian research populations, IHRI represents the most clinically experienced and internationally networked HIV research platform in Southeast Asia.
Thailand is Southeast Asia's pre-eminent clinical research destination; a country whose combination of ICH-aligned regulatory standards, near-universal health coverage at 66 million scale, world-class tropical medicine infrastructure, and two globally irreplaceable disease research niches creates a clinical trial platform of extraordinary depth at a cost fraction of Western equivalents. MORU has defined the global standard for malaria pharmacology and tropical infectious disease clinical investigation for decades. Khon Kaen University's CASCAP is the only viable global platform for pivotal cholangiocarcinoma trials, and the National Centre for Blood Diseases holds the world's most comprehensive thalassaemia patient registry. Thailand's landmark HIV research history; including the RV144 trial; has built an investigator community whose clinical trial experience in HIV and infectious disease is matched only by sub-Saharan Africa and the US/EU at far higher cost. For sponsors developing programs in tropical medicine, hepatology, haemoglobinopathy, biliary oncology, or any Asian-prevalent disease indication, Thailand belongs at the centre of any Asia-Pacific clinical trial plan.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.